Shmuel Ben Zvi
Director/Board Member at BANK LEUMI LE-ISRAEL B.M.
Net worth: - $ as of 30/04/2024
Shmuel Ben Zvi active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BANK LEUMI LE-ISRAEL B.M. | Director/Board Member | 29/07/2015 | - |
| Independent Dir/Board Member | 29/07/2015 | - | |
| PROTALIX BIOTHERAPEUTICS, INC. | Director/Board Member | 30/06/2022 | - |
| Independent Dir/Board Member | 30/06/2022 | - | |
| Shmuel (Muli) Ben Zvi Ltd. | Corporate Officer/Principal | - | - |
Career history of Shmuel Ben Zvi
Former positions of Shmuel Ben Zvi
| Companies | Position | Start | End |
|---|---|---|---|
| NOTABLE LABS, LTD. | Director/Board Member | 01/09/2018 | 16/10/2023 |
| Independent Dir/Board Member | 01/09/2018 | 16/10/2023 | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01/01/2004 | 01/12/2014 |
| Israel Ministry of Defense | Corporate Officer/Principal | 01/01/2000 | 01/01/2004 |
| SOL-GEL TECHNOLOGIES LTD. | Director/Board Member | 01/01/2018 | - |
| Independent Dir/Board Member | 01/01/2018 | - |
Training of Shmuel Ben Zvi
| Tel-Aviv University | Doctorate Degree |
Statistics
International
| Israel | 8 |
| United States | 2 |
Operational
| Director/Board Member | 4 |
| Independent Dir/Board Member | 4 |
| Corporate Officer/Principal | 3 |
Sectoral
| Health Technology | 5 |
| Finance | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| BANK LEUMI LE-ISRAEL B.M. | Finance |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| SOL-GEL TECHNOLOGIES LTD. | Health Technology |
| PROTALIX BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Shmuel (Muli) Ben Zvi Ltd. | |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
| Israel Ministry of Defense | Government |
- Stock Market
- Insiders
- Shmuel Ben Zvi
- Experience